Braidwell »

Dexcom shares owned by Braidwell

Quarter-by-quarter ownership of Dexcom shares owned by Braidwell from 13F filings

Historical chart of Braidwell investment in Dexcom

Tip: Access up to 7 years of quarterly data

All positions including Dexcom held by Braidwell consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Dexcom by Braidwell

Quarter filed Position value Share count Share price at filing
2023-12-31 $47M 45M 1.05
2023-09-30 $36M 38M 0.95

More positions owned by Braidwell

Guardant Health Note 11/1 (Principal)
Bridgebio Pharma Note 2.500% 3/1 (Principal)
Ascendis Pharma A/s Note 2.250% 4/0 (Principal)
Exact Sciences Corp Note 0.375% 3/0 (Principal)
Novocure Note 11/0 (Principal)
Neurocrine Biosciences (NBIX)
Vaxcyte (PCVX)
Xenon Pharmaceuticals (XENE)
Nuvasive Note 0.375% 3/1 (Principal)
Insulet Corp Note 0.375% 9/0 (Principal)
Tandem Diabetes Care Note 1.500% 5/0 (Principal)
Day One Biopharmaceuticals I (DAWN)
Irhythm Technologies (IRTC)
Argenx Se Sponsored Adr (ARGX)
Bridgebio Pharma Note 2.250% 2/0 (Principal)

View all positions for Braidwell

Top funds holding Dexcom

Lazard Asset Management
Calamos Advisors
Citadel Advisors
Braidwell
MacKay Shields
Franklin Resources
Millennium Management
Man Group
Wellington Management Company
Walleye Trading Advisors
Wolverine Asset Management
Shenkman Capital Management
Pier 88 Investment Partners
Zazove Associates
DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main

View all funds holding Dexcom